{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:39:38Z","timestamp":1789605578783,"version":"build-2803163510"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2011,8,27]],"date-time":"2011-08-27T00:00:00Z","timestamp":1314403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2012,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>19\u2010nor\u201014\u2010epi\u201023\u2010yne\u20101,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> (inecalcitol) is a unique vitamin D<jats:sub>3<\/jats:sub> analog. We evaluated the activity of inecalcitol in a human prostate cancer model system. The analog was 11\u2010fold more potent than 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> in causing 50% clonal growth inhibition of androgen\u2010sensitive human prostate cancer LNCaP cells. Inecalcitol, more than 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub>, reduced in a dose\u2010dependent manner the expression levels of the transcription factor ETS variant 1 and the serine\/threonine protein kinase Pim\u20101, both of which are upregulated in prostate cancer. Remarkably, dose challenge experiments revealed that inecalcitol maximal tolerated dose (MTD) by intraperitoneal (i.p.) administration was 30 \u03bcg\/mouse (1,300 \u03bcg\/kg) three times per week, while we previously found that the MTD of 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> is 0.0625 \u03bcg\/mouse; therefore, inecalcitol is 480 times less hypercalcemic than 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub>. Pharmacokinetic studies showed that plasma half\u2010life of inecalcitol were 18.3 min in mice. A xenograft model of LNCaP cells was developed in immunodeficient mice treated with inecalcitol. The tumors of the diluent\u2010treated control mice increased in size but those in the inecalcitol treatment group did not grow. Our data suggest that inecalcitol inhibits androgen\u2010responsive prostate cancer growth <jats:italic>in vivo<\/jats:italic> and should be examined either alone or with other chemotherapy in clinical trials in individuals with rising serum prostate\u2010specific antigen after receiving either surgery or irradiation therapy with curative intent.<\/jats:p>","DOI":"10.1002\/ijc.26279","type":"journal-article","created":{"date-parts":[[2011,7,5]],"date-time":"2011-07-05T13:09:57Z","timestamp":1309871397000},"page":"2464-2473","source":"Crossref","is-referenced-by-count":47,"title":["Inecalcitol, an analog of 1\u03b1,25(OH)<sub>2<\/sub>D<sub>3<\/sub>, induces growth arrest of androgen\u2010dependent prostate cancer cells"],"prefix":"10.1002","volume":"130","author":[{"given":"Ryoko","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Delansorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan B.","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayuki","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc H.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Phillip","family":"Koeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009584"},{"key":"e_1_2_6_3_2","first-page":"667","article-title":"Apoptosis induction by 1alpha,25\u2010dihydroxyvitamin D3 in prostate cancer","volume":"1","author":"Guzey M","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207461"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306340200"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2001-210109"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3796"},{"key":"e_1_2_6_8_2","first-page":"2673","article-title":"Two novel 14\u2010epi\u2010analogues of 1,25\u2010dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo","volume":"60","author":"Verlinden L","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26273"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/35090585"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.06.044"},{"key":"e_1_2_6_12_2","first-page":"8079","article-title":"Overexpression of the oncogenic kinase Pim\u20101 leads to genomic instability","volume":"63","author":"Roh M","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_13_2","first-page":"e9584","article-title":"A role for polyploidy in the tumorigenicity of Pim\u20101\u2010expressing human prostate and mammary epithelial cells","volume":"5","author":"Roh M","year":"2008","journal-title":"PLoS One"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2402"},{"key":"e_1_2_6_15_2","first-page":"e9584","article-title":"Overexpression of Full\u2010Length ETV1 Transcripts in Clinical Prostate Cancer Due to Gene Translocation","volume":"5","author":"Gasi D","year":"2011","journal-title":"PLoS One"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/me.2006-0480"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.13.1107"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood.V88.6.2201.bloodjournal8862201","article-title":"A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia","volume":"88","author":"Munker R","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2006.04.003"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0536"},{"key":"e_1_2_6_21_2","first-page":"19","article-title":"ERG upregulation and related ETS transcription factors in prostate cancer","volume":"30","author":"Rostad K","year":"2007","journal-title":"Int J Oncol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06024"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3619"},{"key":"e_1_2_6_24_2","first-page":"283","article-title":"Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo","volume":"23","author":"Vegesna V","year":"2003","journal-title":"Anticancer Res"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.4.625"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.008730"},{"key":"e_1_2_6_27_2","first-page":"89","article-title":"Characterization of five 19\u2010nor\u2010analogs of 1alpha,25(OH)2\u2010Vitamin D3 with 20\u2010cyclopropyl\u2010modified side\u2010chains: implications for ligand binding and calcemic properties","author":"Olivera CJ","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076336"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0620427"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq875"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.26.18659"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M404440200"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(02)00347-6"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.26279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.26279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:09:07Z","timestamp":1697458147000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.26279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,27]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,5,15]]}},"alternative-id":["10.1002\/ijc.26279"],"URL":"https:\/\/doi.org\/10.1002\/ijc.26279","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,27]]}}}